ZEO ScientifiX Inc

zeoscientifix.com

What Do They Do?

Develops and sells regenerative biologics and related services—including perinatal-derived products, a patient-blood-based service, and topical products—to doctors and clinics.

How Do They Make Money?

Customers pay for biologic products and related services when a shipment is delivered and accepted; products stored at the company’s facility are delivered later at the customer’s direction.

FY2024 revenue

Who Are Their Customers?

Doctors and clinics buy the company’s products and services through in-house and contracted sales personnel and independent distributors. Its customer base spans the United States and worldwide.

Customers above 10% of revenue, FY2025

of revenue from three customers (14%, 12%, 11%)

FY2024: 26% from two customers

Do Revenues Turn Into Profits?

No. It lost $5.5M in FY2024.

Operating income, FY2024

−104% of revenue

▲ +1% (Loss) vs FY2023 (−$5.3M, −115%)

Net income, FY2024

−106% of revenue

▲ +17% (Loss) vs FY2023 (−$4.7M, −102%)

Free cash flow, FY2024

−14% of revenue

How Are They Changing?

Since the FY2024 annual report

Latest quarter: Q2 FY2026, the three months to Apr 30, 2026

Revenue: ▲ +125%; vs $1.1M in Q2 FY2025
Net income: ▼ −90% (Loss); vs −$1.4M in Q2 FY2025

Flat. Revenue was $5.2M in FY2024, about the same as the $5.6M of FY2020.

Florida commercial strategy The earlier report emphasized clinical trials, international sales and new products; the latest adds commercial sales strategies for therapies permitted under a new Florida law.

Topical aesthetic products The earlier overview centered on perinatal-derived biologics; the latest also describes products using proprietary ingredients for topical aesthetic applications.

Who Do They Compete With?

Competes with Kimera Labs, Frontier Biologics, Platinum Biologics, Benev, Exocel Bio, Re-gen Active Lab, Neobiosis, MiMedix Group, Invitrx Therapeutics, DermaSciences, Signature Biologics, Direct Biologics, Vitti Labs, and Regenexx

Comments